Single-cell Genetic Analysis Validates Cytopathological Identification of Circulating Cancer Cells in Patients with Clear Cell Renal Cell Carcinoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 May 8

PMID 29732003

Citations 14

Authors

Lucile Broncy

Basma Ben Njima

Arnaud Mejean

Christophe Beroud

Khaled Ben Romdhane

Marius Ilie

Veronique Hofman

Jane Muret

Paul Hofman

Habiba Chaabouni Bouhamed

And Patrizia Paterlini-Brechot

Affiliations

Soon will be listed here.

Abstract

Context: Circulating Rare Cells (CRC) are non-haematological cells circulating in blood. They include Circulating Cancer Cells (CCC) and cells with uncertain malignant features (CRC-UMF) according to cytomorphology. Clear cell renal cell carcinomas frequently bear a mutated Von Hippel-Lindau (VHL) gene.

Aim: To match blind genetic analysis of CRC and tumor samples with CRC cytopathological diagnosis.

Results: 29/30 patients harboured CRC (20 harboured CCC, 29 CRC-UMF) and 25/29 patients carried VHL mutations in their tumour. 205 single CRC (64 CCC, 141 CRC-UMF) provided genetic data. 57/57 CCC and 104/125 CRC-UMF from the 25 patients with VHL-mutated tumor carried the same VHL mutation detected in the tumor. Seven CCC and 16 CRC-UMF did not carry VHL mutations but were found in patients with wild-type VHL tumor tissue.

Conclusions: All the CCC and 83,2% (104/125) of the CRC-UMF were found to carry the same VHL mutation identified in the corresponding tumorous tissue, validating cytopathological identification of CCC in patients with clear cell renal cell carcinoma.

Methods: The blood of 30 patients with clear cell renal cell carcinoma was treated by ISET for CRC isolation, cytopathology and single-cell VHL mutations analysis, performed blindly and compared to VHL mutations of corresponding tumor tissues and leukocytes.

Citing Articles

Liquid biopsy for Renal Cell Carcinoma: A comprehensive review of techniques, applications, and future prospects.

Jani C, Abdallah N, Tan A, McKay R Kidney Cancer. 2025; 8(1):205-225.

PMID: 39886007 PMC: 11781563. DOI: 10.1177/24684570241303346.

Diagnostic liquid biopsy biomarkers in renal cell cancer.

Zieren R, Zondervan P, Pienta K, Bex A, de Reijke T, Bins A Nat Rev Urol. 2023; 21(3):133-157.

PMID: 37758847 DOI: 10.1038/s41585-023-00818-y.

Polyploid Giant Cancer Cells Are Frequently Found in the Urine of Prostate Cancer Patients.

Garrido Castillo L, Anract J, Barry Delongchamps N, Huillard O, BenMohamed F, Decina A Cancers (Basel). 2023; 15(13).

PMID: 37444476 PMC: 10340459. DOI: 10.3390/cancers15133366.

Clinical Validation of a Size-Based Microfluidic Device for Circulating Tumor Cell Isolation and Analysis in Renal Cell Carcinoma.

Leitao T, Corredeira P, Kucharczak S, Rodrigues M, Piairo P, Rodrigues C Int J Mol Sci. 2023; 24(9).

PMID: 37176111 PMC: 10178884. DOI: 10.3390/ijms24098404.

Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application.

Li M, Li L, Zheng J, Li Z, Li S, Wang K Mol Cancer. 2023; 22(1):37.

PMID: 36810071 PMC: 9942319. DOI: 10.1186/s12943-023-01745-7.

References

Razafinjatovo C, Bihr S, Mischo A, Vogl U, Schmidinger M, Moch H . Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer. 2016; 16:638. PMC: 4987997. DOI: 10.1186/s12885-016-2688-0. View

Jang S, Gardner J, Ro J . Diagnostic approach and prognostic factors of cancers. Adv Anat Pathol. 2011; 18(2):165-72. DOI: 10.1097/PAP.0b013e31820cb39e. View

Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T . Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013; 45(8):860-7. DOI: 10.1038/ng.2699. View

Abbosh C, Birkbak N, Wilson G, Jamal-Hanjani M, Constantin T, Salari R . Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017; 545(7655):446-451. PMC: 5812436. DOI: 10.1038/nature22364. View

Kallergi G, Politaki E, Alkahtani S, Stournaras C, Georgoulias V . Evaluation of Isolation Methods for Circulating Tumor Cells (CTCs). Cell Physiol Biochem. 2016; 40(3-4):411-419. DOI: 10.1159/000452556. View

E Silva V, Chinen L, Abdallah E, Damascena A, Paludo J, Chojniak R . Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. Onco Targets Ther. 2016; 9:7503-7513. PMC: 5167467. DOI: 10.2147/OTT.S115268. View

Pritchett T, Bader H, Henderson J, Hsu T . Conditional inactivation of the mouse von Hippel-Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney. Oncogene. 2014; 34(20):2631-9. DOI: 10.1038/onc.2014.197. View

Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin Jr W . Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002; 1(3):237-46. DOI: 10.1016/s1535-6108(02)00043-0. View

Paterlini-Brechot P . Circulating Tumor Cells: Who is the Killer?. Cancer Microenviron. 2014; 7(3):161-76. PMC: 4275541. DOI: 10.1007/s12307-014-0164-4. View

10.

Ashida S, Okuda H, Chikazawa M, Tanimura M, Sugita O, Yamamoto Y . Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma. Clin Cancer Res. 2000; 6(10):3817-22. View

11.

Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M . VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 2000; 60(7):1942-8. View

12.

Bluemke K, Bilkenroth U, Meye A, Fuessel S, Lautenschlaeger C, Goebel S . Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev. 2009; 18(8):2190-4. DOI: 10.1158/1055-9965.EPI-08-1178. View

13.

Buim M, Fanelli M, Souza V, Romero J, Abdallah E, Mello C . Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. Cancer Biol Ther. 2015; 16(9):1289-95. PMC: 4622515. DOI: 10.1080/15384047.2015.1070991. View

14.

Banks R, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D . Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006; 66(4):2000-11. DOI: 10.1158/0008-5472.CAN-05-3074. View

15.

Hofman V, Long E, Ilie M, Bonnetaud C, Vignaud J, Flejou J . Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology. 2011; 23(1):30-8. DOI: 10.1111/j.1365-2303.2010.00835.x. View

16.

Nickerson M, Jaeger E, Shi Y, Durocher J, Mahurkar S, Zaridze D . Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008; 14(15):4726-34. PMC: 2629664. DOI: 10.1158/1078-0432.CCR-07-4921. View

17.

Laget S, Broncy L, Hormigos K, Dhingra D, BenMohamed F, Capiod T . Technical Insights into Highly Sensitive Isolation and Molecular Characterization of Fixed and Live Circulating Tumor Cells for Early Detection of Tumor Invasion. PLoS One. 2017; 12(1):e0169427. PMC: 5218415. DOI: 10.1371/journal.pone.0169427. View

18.

Saker A, Benachi A, Bonnefont J, Munnich A, Dumez Y, Lacour B . Genetic characterisation of circulating fetal cells allows non-invasive prenatal diagnosis of cystic fibrosis. Prenat Diagn. 2006; 26(10):906-16. DOI: 10.1002/pd.1524. View

19.

Alix-Panabieres C, Pantel K . Challenges in circulating tumour cell research. Nat Rev Cancer. 2014; 14(9):623-31. DOI: 10.1038/nrc3820. View

20.

Mandriota S, Turner K, Davies D, Murray P, Morgan N, Sowter H . HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 2002; 1(5):459-68. DOI: 10.1016/s1535-6108(02)00071-5. View